Multimodal Ocular Imaging in Neurodegeneration

Exclusion Criteria

• •Preexisting retinal or optic nerve disorder including macular degeneration, diabetic retinopathy, retinal dystrophy, and glaucoma
• •Anterior segment abnormalities of the eye limiting ocular imaging (e.g. corneal disorders, dense cataract).
• •Use of medications with known effects on the retina or optic nerve (e.g. hydroxychloroquine, ethambutol).
• •Pregnant or lactating women.
• •Prisoners.
• •Subjects with advanced dementia who cannot be independently and reliably positioned at the ocular imaging device for reliable imaging.
• •Subjects with contraindications to magnetic resonance (MR) imaging, including pacemakers or claustrophobia.
• •Evidence of large vessel stroke or mass lesion identified on MR imaging.
• •Subjects limited by participation in research procedures involving ionizing radiation.
• •Subjects who are already participating in another clinical study or clinical trial
• •Participants with a clinically significant or unstable medical or surgical condition that, in the opinion of any of the investigators, might preclude safe completion of the study or might affect the results of the study. These include conditions causing significant central nervous system or autonomic dysfunction, such as congestive heart failure, recent (\<6 months) myocardial infarction, thrombocytopenia (\<50 x 10(9)/L), immunosuppressed state, severe uncontrolled hypertension, severe cardiopulmonary disease, severe anemia (hemoglobin \<8g/dl), severe liver or kidney disease (creatinine \>2.3 mg/dl) uncontrolled diabetes mellitus (HgbA1c \>10g%), alcoholism, malignant neoplasms, amyloidosis, uncontrolled hypothyroidism, unstable peripheral neuropathies, concurrent infections, orthopedic problems that compromise mobility and activities of daily living, severe cerebrovascular accidents (causing symptoms such as hemiplegia, aphasia and non-dominant parietal lobe syndrome), history of exposure to neurotoxins or neuroactive drugs, or parkinsonism due to drugs (including neuroleptics, alpha-methyldopa, reserpine, metoclopramide).